The latest approaches in synthetic lethality aim to use various PARP1 inhibitors (talazoparib, veliparib, rucaparib, niraparib) for the treatment of cancers with defects other than BRCA1 deficiencies, including defects in PALB2, FANCD2, RAD51, ATM, MRE11, p53, XRCC1 and LSD1[22]. The gene discussed is TP53; the disease is cancer.